Payment & Shipping Terms:
|Name:||Nolvadex / Tamoxifen Citrate||Cas:||54965-24-1|
|Appearance:||White Crystalline Powder||Packaging:||Discreet Packaging|
bodybuilding anti estrogen,
anti estrogen medicine
|Product Name:||Tamoxifen citrate|
|Synonyms:||terimon;trans-1-(p-beta-dimethylaminoethoxyphenyl)-1,2-diphenylbut-1-enecitrate;y-1,2,3-propanetricarboxylate(1:1);z-tamoxifencitrate;Z-1-(P-DIMETHYLAMINOETHOXYPHENYL)-1,2-DIPHENYL-1-BUTENE CITRATE;[Z]-1-[P-DIMETHYLAMINOETHOXYPHENYL]-1,2-DIPHENYL-1-BUTENE CITRATE SALT;(z)-2-[4-(1,2-diphenyl-1-butenyl)phenoxyl]-n,n-dimethyl-ethanamine-citrate;(Z)-2-[4-(1,2-DIPHENYL-1-BUTENYL)PHENOXY]-N,N-DIMETHYLETHANAMINE CITRATE|
|Product Categories:||API;SOLTAMOX;-;Inhibitors;Active Pharmaceutical Ingredients;Antitumors for Research and Experimental Use;Biochemistry;API's;Intracellular receptor;Steroid and Hormone|
|Tamoxifen citrate Chemical Properties|
|Melting point||140-144 °C|
|solubility||methanol: soluble50mg/mL, clear, colorless|
|color||White to off-white|
|Water Solubility||slightly soluble|
|Sensitive||Light Sensitive & Hygroscopic|
|CAS DataBase Reference||54965-24-1(CAS DataBase Reference)|
|Tamoxifen citrate Usage And Synthesis|
|Overview||Tamoxifen, sold under the brand name Nolvadex among others, is a medication that is used to prevent breast cancer in women and treat breast cancer in women and men. The introduction of the anti-oestrogen tamoxifen in the early 1970s represented a landmark in the treatment of breast cancer. Over 40 years later, tamoxifen has been shown to be effective not only for early and advanced breast cancer, but also for ductal carcinoma in situ (DCIS) and the chemoprevention of breast cancer in high-risk pre- and post- menopausal women. Indeed, tamoxifen is the benchmark against which newer endocrine therapies continue to be measured.
Breast cancer is the second highly pervasive cause of mortalities in the world. It does not cover only women but also men and food animals. Metastatic breast cancer is more drastic as the main causative agent is not known. Although, multiple causes have been known to be involved in the metastatic breast cancer, but still chemotherapy is a question to absolutely treat this cancer. 1.3 million women suffer from breast cancer in United States. Similarly 1 out of every 7 women had breast cancer. Not only humans but also animals become victim of breast cancer. Tamoxifen was introduced by AstraZeneca of UK for the first time and being frequently prescribed as hormonal therapy for estrogen positive breast cancer in the clinics of Pakistan and Australia. It is far better to use right medicine with right dose at the right stage of the disease to opt maximum curative results. The exact kinetic and dynamic mechanism within human is necessary for manufacturing a drug against any disease.
Figure 1 the chemical structure of Tamoxifen
|Application||Long term use of Tamoxifen as prophylaxis is recommended and found useful with decrease in recurrence rate of breast cancer. The risk-lowering effect of Tamoxifen appears to persist for at least 10 years, yet most side effects of Tamoxifen do not continue after the 5-year treatment period. Thus the long term treatment with Tamoxifen is appreciated. Tamoxifen has been the adjuvant therapy of choice for postmenopausal, node-positive, and estrogen or progesterone receptor positive women since the mid-1980s, and for postmenopausal, node-negative, and estrogen or progesterone receptor-positive women since the early 1990s. It is also being used in many cases of node-negative and receptor-positive premenopausal women. A high proportion (40-60%) of all women who undergo potentially curative surgery for breast cancer now receive adjuvant Tamoxifen therapy for a period of 2 to 5 years. It was first approved for pharmaceutical use in the United Kingdom in 1973 and in the United States in 1977; Tamoxifen is presently registered in 97 countries. Tamoxifen use has been estimated at more than 7 million patient/years. The usual dose in the United States and the United Kingdom is 20 mg/day for 1 to 2 years whereas in continental Europe, usual doses are 30 to 40 mg/day.
Tamoxifen is used for the treatment of invasive breast cancer in men and women, the most common type of breast cancer, following surgery and/or radiation and for preventing invasive breast cancer in women at high risk for developing it. Tamoxifen also is used for the treatment of women following surgery and radiation for a less common type of breast cancer called ductal carcinoma in situ (DCIS or Intraductal Carcinoma). Women who have had DCIS are at high risk for developing invasive breast cancer at a later date, and tamoxifen prevents development of the invasive cancer in almost half of the women during the first five years of treatment. Occasionally, tamoxifen is used to stimulate ovulation.
|Mode of action||Tamoxifen is being frequently prescribed as hormonal therapy of estrogen positive breast cancer in the clinics of Pakistan. There is a competitive binding of tamoxifen to estrogen receptors in cancer cells and other tissue targets, and this in turn produces a nuclear complex that decreases DNA synthesis and inhibits estrogen action. It is a non-steroidal agent with potential anti estrogenic abilities which occupies estrogen binding sites in breast tissue and metabolized by the liver enzyme Cyp2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6), rendering active metabolites of Tamoxifen includes N-desmethyl tamoxifen, endoxifen and 4 hydroxy tamoxifen. Tamoxifen is known as a classic pro-drug requiring metabolic activation to start its pharmacological activity. Mainly 2D6 of cytochrome 450 appears to be the rate-limiting enzyme converting the pharmacologically inactive metabolites (Tamoxifen and NDM) to endoxifen, and further contributes to the formation of 4-OH-Tam from Tamoxifen. The findings depict that both genetic and environmental (drug-induced) factors that change CYP2D6 enzyme activity affect Tamoxifen treatment results. Research was done to check the breast density after use of Tamoxifen in patients. MRI of breast was performed after Tamoxifen use. It was concluded that with the use of Tamoxifen breast cancer is reduced hence the breast density came out to be less.|
We're specialized in pharma.raw materials ( hormone steroid powders, Steroids injectable liquids,peptides,Sarms), our company integrates R&D, producing, operating and marketing into an organic whole. We have authority of export and import, and have experience of export for 15 years.
Major Market: United States, United Kingdom, Australia, Canada, Sweden, Russia, Poland, Brazil, Israel, Netherlands, Germany,Spain, Switzerland, Poland and so on.
Package:Disguised & Discreet pkg
Delivery: sent out the goods within 24hours after receiving payment.
Custom Pass rate:99%
Resend policy is available if the parcle is seized or any quality problems been found.
After-sale Service :
Discounts are available for our second-time customers. We can provide recipes and professional suggestions to promote yourselves. Tracking number and packing photos can be given quickly after your goods sent. We are always here waiting for you!
Our main products are wait for you:
Anabolic Steroid Powders
Semi-finished Steroid liquid
Male enhancement powder
Pain Killer Powders
Solvents for Steroids: BA, BB, GSO, Guaiacol, EO, PEG etc.
Tools & Devices: Filter,Crimper,Vials, caps, ect.
Contact Person: Lin.z